血漿誘導体の世界市場:タイプ別(アルブミン、第VIII因子、第IX因子、免疫グロブリン、高力価免疫グロブリン、その他)、用途別(血友病、低ガンマグロブリン血症、免疫不全症、フォンヴィレブランド病(VWD)、その他)、エンドユーザー別(病院、診療所、その他)

◆英語タイトル:Blood Plasma Derivatives Market by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrands Disease (vWD), and Other Application), and End User (Hospitals, Clinics, and Other End Users) - Global Opportunity Analysis and Industry Forecast, 2016-2023
◆商品コード:AMR805002
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2018年4月20日
◆ページ数:240
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥606,810見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥728,850見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥1,016,435見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本資料は、血漿誘導体の世界市場について調べ、血漿誘導体の世界規模、市場動向、市場環境、タイプ別(アルブミン、第VIII因子、第IX因子、免疫グロブリン、高力価免疫グロブリン、その他)分析、用途別(血友病、低ガンマグロブリン血症、免疫不全症、フォンヴィレブランド病(VWD)、その他)分析、エンドユーザー別(病院、診療所、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・血漿誘導体の世界市場概要
・血漿誘導体の世界市場環境
・血漿誘導体の世界市場動向
・血漿誘導体の世界市場規模
・血漿誘導体の世界市場:タイプ別(アルブミン、第VIII因子、第IX因子、免疫グロブリン、高力価免疫グロブリン、その他)
・血漿誘導体の世界市場:用途別(血友病、低ガンマグロブリン血症、免疫不全症、フォンヴィレブランド病(VWD)、その他)
・血漿誘導体の世界市場:エンドユーザー別(病院、診療所、その他)
・血漿誘導体の世界市場:地域別市場規模・分析
・血漿誘導体の北米市場規模・予測
・血漿誘導体のアメリカ市場規模・予測
・血漿誘導体のヨーロッパ市場規模・予測
・血漿誘導体のアジア市場規模・予測
・血漿誘導体の日本市場規模・予測
・血漿誘導体の中国市場規模・予測
・関連企業情報
【レポートの概要】

Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

The global blood plasma derivatives market was valued at $23,613 million in 2016, and is projected to reach $44,333 million at a CAGR of 9.3% from 2017 to 2023. The major factor that contributes towards the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors boosting the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The global blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand’s Disease (vWD), and other application. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed for North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global blood plasma derivatives market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Type

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

By Application

Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
von Willebrand’s disease (vWD)
Other Application

By End User

Hospitals
Clinics
Other End Users

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Grifols, S.A.
SK Plasma Co., Ltd.
Fusion Health Care Pvt. Ltd.
Biotest AG
Green Cross Corporation
Baxter International Inc.
LFB S.A.
Octapharma AG
CSL Limited
Shire Plc.

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Type
1.3.2. By Application
1.3.3. By End User
1.3.4. By Region
1.3.5. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. High prevalence of life threatening diseases
3.4.1.2. Growth in awareness about blood and plasma donation
3.4.1.3. Rise in geriatric population
3.4.1.4. High adoption of blood plasma derivatives

3.4.2. Restraints

3.4.2.1. High cost of blood plasma derivatives based therapy
3.4.2.2. Risks associated with plasma derivatives

3.4.3. Opportunities

3.4.3.1. Development of better methods for plasma derivatives manufacturing
3.4.3.2. Opportunities in emerging economies

3.4.4. Impact analyses

3.5. Government regulations

3.5.1. Plasma derivatives regulations in United States and Europe

CHAPTER 4: BLOOD PLASMA DERIVATIVES MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Factor VIII

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Factor IX

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Immunoglobulin

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Hyperimmune globulin

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Hemophilia

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Hypogammaglobulinemia

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Immunodeficiency diseases

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. von Willebrand’s disease (vWD)

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Other application

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

CHAPTER 6: BLOOD PLASMA DERIVATIVES MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Clinics

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Other end users

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: BLOOD PLASMA DERIVATIVES MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America blood plasma derivatives market, by country

7.2.2.1. U.S.

7.2.2.1.1. Market size and forecast, by type
7.2.2.1.2. Market size and forecast, by application
7.2.2.1.3. Market size and forecast, by end user

7.2.2.2. Canada

7.2.2.2.1. Market size and forecast, by type
7.2.2.2.2. Market size and forecast, by application
7.2.2.2.3. Market size and forecast, by end user

7.2.2.3. Mexico

7.2.2.3.1. Market size and forecast, by type
7.2.2.3.2. Market size and forecast, by application
7.2.2.3.3. Market size and forecast, by end user

7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Market size and forecast, by type
7.3.2.1.2. Market size and forecast, by application
7.3.2.1.3. Market size and forecast, by end user

7.3.2.2. France

7.3.2.2.1. Market size and forecast, by type
7.3.2.2.2. Market size and forecast, by application
7.3.2.2.3. Market size and forecast, by end user

7.3.2.3. UK

7.3.2.3.1. Market size and forecast, by type
7.3.2.3.2. Market size and forecast, by application
7.3.2.3.3. Market size and forecast, by end user

7.3.2.4. Italy

7.3.2.4.1. Market size and forecast, by type
7.3.2.4.2. Market size and forecast, by application
7.3.2.4.3. Market size and forecast, by end user

7.3.2.5. Spain

7.3.2.5.1. Market size and forecast, by type
7.3.2.5.2. Market size and forecast, by application
7.3.2.5.3. Market size and forecast, by end user

7.3.2.6. Rest of Europe

7.3.2.6.1. Market size and forecast, by type
7.3.2.6.2. Market size and forecast, by application
7.3.2.6.3. Market size and forecast, by end user

7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Market size and forecast, by type
7.4.2.1.2. Market size and forecast, by application
7.4.2.1.3. Market size and forecast, by end user

7.4.2.2. China

7.4.2.2.1. Market size and forecast, by type
7.4.2.2.2. Market size and forecast, by application
7.4.2.2.3. Market size and forecast, by end user

7.4.2.3. India

7.4.2.3.1. Market size and forecast, by type
7.4.2.3.2. Market size and forecast, by application
7.4.2.3.3. Market size and forecast, by end user

7.4.2.4. Australia

7.4.2.4.1. Market size and forecast, by type
7.4.2.4.2. Market size and forecast, by application
7.4.2.4.3. Market size and forecast, by end user

7.4.2.5. South Korea

7.4.2.5.1. Market size and forecast, by type
7.4.2.5.2. Market size and forecast, by application
7.4.2.5.3. Market size and forecast, by end user

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Market size and forecast, by type
7.4.2.6.2. Market size and forecast, by application
7.4.2.6.3. Market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Market size and forecast, by type
7.5.2.1.2. Market size and forecast, by application
7.5.2.1.3. Market size and forecast, by end user

7.5.2.2. Saudi Arabia

7.5.2.2.1. Market size and forecast, by type
7.5.2.2.2. Market size and forecast, by application
7.5.2.2.3. Market size and forecast, by end user

7.5.2.3. South Africa

7.5.2.3.1. Market size and forecast, by type
7.5.2.3.2. Market size and forecast, by application
7.5.2.3.3. Market size and forecast, by end user

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Market size and forecast, by type
7.5.2.4.2. Market size and forecast, by application
7.5.2.4.3. Market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

8.1. Baxter International Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Biotest AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. CSL Limited

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. Fusion Health Care Pvt. Ltd.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. Grifols S.A.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Green Cross Holdings Corporation (Green Cross Corp.)

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. LFB SA (LFB Biotechnologies SAS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Octapharma AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Shire Plc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SK chemicals (SK Plasma Co., Ltd.)

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

TABLE 01. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 02. PLASMA-DERIVED ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 03. PLASMA-DERIVED FACTOR VIII MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. PLASMA-DERIVED FACTOR IX MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. PLASMA-DERIVED IMMUNOGLOBULINS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. PLASMA-DERIVED HYPERIMMUNE GLOBULIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 07. OTHERS PLASMA DERIVED PRODUCTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 09. BLOOD PLASMA DERIVATIVES MARKET FOR HEMOPHILIA, BY REGION, 2016-2023 ($MILLION)
TABLE 10. BLOOD PLASMA DERIVATIVES MARKET FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2016-2023 ($MILLION)
TABLE 11. BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNODEFICIENCY DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 12. BLOOD PLASMA DERIVATIVES MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2016-2023 ($MILLION)
TABLE 13. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 15. BLOOD PLASMA DERIVATIVES MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. BLOOD PLASMA DERIVATIVES MARKET FOR CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER END USERS, BY REGION, 2016-2023 ($MILLION)
TABLE 18. BLOOD PLASMA DERIVATIVES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 22. U.S. BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 23. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 24. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 25. CANADA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 27. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. MEXICO BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 32. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 34. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. GERMANY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 37. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. FRANCE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 39. UK BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. UK BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. UK BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 42. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 43. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. ITALY BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 45. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. SPAIN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. REST OF EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 51. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 52. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 53. EUROPE BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 55. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 56. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 57. JAPAN BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 58. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. CHINA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 61. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 62. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 63. INDIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 64. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 65. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 66. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 67. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 68. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 76. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 77. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 78. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 79. BRAZIL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 80. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 81. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 82. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 83. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 86. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 90. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 91. LAMEA BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 92. BAXTER: COMPANY SNAPSHOT
TABLE 93. BAXTER: OPERATING SEGMENTS
TABLE 94. BAXTER: PRODUCT PORTFOLIO
TABLE 95. BIOTEST: COMPANY SNAPSHOT
TABLE 96. BIOTEST: OPERATING SEGMENTS
TABLE 97. BIOTEST: OPERATING SEGMENT
TABLE 98. CSL: COMPANY SNAPSHOT
TABLE 99. CSL: PRODUCT SEGMENTS
TABLE 100. CSL: PRODUCT PORTFOLIO
TABLE 101. FUSION HEALTHCARE: COMPANY SNAPSHOT
TABLE 102. FUSION HEALTHCARE: OPERATING DIVISION
TABLE 103. FUSION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104. GRIFOLS: COMPANY SNAPSHOT
TABLE 105. GRIFOLS: OPERATING SEGMENTS
TABLE 106. GRIFOLS: PRODUCT PORTFOLIO
TABLE 107. GREEN CROSS: COMPANY SNAPSHOT
TABLE 108. GREEN CROSS: OPERATING SEGMENTS
TABLE 109. GREEN CROSS: PRODUCT PORTFOLIO
TABLE 110. LFB: COMPANY SNAPSHOT
TABLE 111. LFB: PRODUCT SEGMENTS
TABLE 112. LFB: PRODUCT PORTFOLIO
TABLE 113. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 114. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 115. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 116. SHIRE: COMPANY SNAPSHOT
TABLE 117. SHIRE: PRODUCT PORTFOLIO
TABLE 118. SK CHEMICALS: COMPANY SNAPSHOT
TABLE 119. SK CHEMICALS: OPERATING SEGMENTS
TABLE 120. SK CHEMICALS: PRODUCT PORTFOLIO

FIGURE 01. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. TOP PLAYER POSITIONING, 2016
FIGURE 07. PERCENTAGE OF PEOPLE WITH HEMOPHILIA A IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 08. IMPACT ANALYSES
FIGURE 09. COMPARATIVE ANALYSIS OF PLASMA-DERIVED ALBUMIN MARKET, 2016-2023 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF PLASMA-DERIVED FACTOR VIII MARKET, 2016-2023 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF PLASMA DERIVED FACTOR IX MARKET, 2016-2023 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PLASMA-DERIVED IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PLASMA DERIVED HYPERIMMUNE GLOBULIN MARKET, 2016-2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTHERS PLASMA-DERIVED PRODUCTS MARKET, 2016-2023 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HEMOPHILIA MARKET, 2016-2023 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HYPOGAMMAGLOBULINEMIA MARKET, 2016-2023 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR IMMUNODEFICIENCY DISEASES MARKET, 2016-2023 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR VON WILLEBRAND DISEASE MARKET, 2016-2023 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATIONS, 2016-2023 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR HOSPITALS MARKET, 2016-2023 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR CLINICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF BLOOD PLASMA DERIVATIVES FOR OTHER END USER MARKET, 2016-2023 ($MILLION)
FIGURE 23. PERCENTAGE OF PEOPLE WITH HEMOPHILIA B IN THE U.S. IN 2016, BY AGE GROUP
FIGURE 24. AGE DISTRIBUTION OF THE UK POPULATION, 2006 TO 2046 (IN PERCENTAGE)
FIGURE 25. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 26. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 27. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 28. BIOTEST: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. CSL: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. GRIFOLS: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. GRIFOLS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. GRIFOLS: REVENUE SHARE BY GEPGRAPHY, 2016 (%)
FIGURE 37. GREEN CROSS: NET SALES, 2014-2015 ($MILLION)
FIGURE 38. GREEN CROSS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. GREEN CROSS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. LFB: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 42. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. OCTAPHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 44. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. SK CHEMICALS: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. SK CHEMICALS: REVENUE SHARE BY SEGMENT, 2016 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血漿誘導体の世界市場:タイプ別(アルブミン、第VIII因子、第IX因子、免疫グロブリン、高力価免疫グロブリン、その他)、用途別(血友病、低ガンマグロブリン血症、免疫不全症、フォンヴィレブランド病(VWD)、その他)、エンドユーザー別(病院、診療所、その他)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆